Organization (Other)
Helsinn Healthcare SA
ClinicalTrials.gov lists Helsinn Healthcare SA as lead sponsor of 32 trials. It has 12 active development programs and 13 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Helsinn Healthcare SA: 32 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Vomiting | 17 |
| Nausea | 6 |
| Cholangiocarcinoma | 4 |
| Cachexia | 3 |
| Lung Neoplasms | 3 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 4 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 6 |
| 2016 | 1 |
| 2015 | 5 |
| 2014 | 3 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Palonosetron | Vomiting | Phase 3 | 7 |
| Anamorelin HCl | Lung Neoplasms | Phase 3 | 2 |
| Anamorelin HCl | Carcinoma, Non-Small-Cell Lung | Phase 3 | 2 |
| Anamorelin HCl | Cachexia | Phase 3 | 2 |
| Anamorelin HCl | Weight Loss | Phase 3 | 2 |
Showing 5 of 12 active programs.
Approved assets (13)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Dexamethasone, 8 mg (oral) or equivalent IV dose | 1 |
| Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV) | 1 |
| NEPA | 1 |
| Palonosetron | 7 |
| DEXAMETHASONE | 6 |
Showing 5 of 13 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 54% hit target (n=13) | 43% on time (n=14) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cancer medicine | 2 |
| Future oncology (London, England) | 2 |
| The Lancet. Oncology | 2 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
| Blood advances | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 66 | 12 | 2025-10-14 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Parexel | Uses vendor | 3 |
| PSI CRO (United Kingdom) | Uses vendor | 2 |
Latest dated events (110)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-08-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 110 events.
Biomarker capability evidence (149)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CSF2 | Trial collaborator | Named in trial inclusion criteria |
| CSF3 | Trial collaborator | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 149 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.